根治性前列腺切除术后早期挽救放疗中低持续或升高PSA患者的预后比较
该回顾性研究比较了根治性前列腺切除术后接受早期挽救放疗(SRT)且未联合雄激素剥夺治疗(ADT)的患者中,低持续PSA与PSA从不可测水平升高的预后差异。结果显示两组在生化无进展生存、无转移生存、无进展生存和总生存上均无显著差异,提示低持续PSA患者预后可能与PSA升高者相当,在无其他危险因素时可考虑省略ADT。
要点
- 低持续PSA组与PSA升高组在BPFS、MFS、PFS和OS上均无显著差异。
- 多因素分析中PSA持续状态不能预测任何生存结局。
- 无其他危险因素时,低持续PSA患者可考虑省略ADT。
核心结论
- 低持续PSA值患者的预后与PSA从不可测水平升高的患者相当。
- 在无其他因素的情况下,这一有利患者群体可考虑省略ADT。
- 需要前瞻性试验验证。
研究设计与样本
- 回顾性比较分析,纳入接受前列腺床SRT且未联合ADT的患者(SRT前PSA≤0.3 ng/ml)。
- 243例患者术后PSA从不可测水平升高(术后PSA≤0.05 ng/ml)。
- 110例患者根治性切除术后PSA持续存在(术后PSA>0.05 ng/ml)。
主要发现
- 低持续PSA组与PSA升高组的BPFS率分别为66.4%和71.6%(p=0.253;中位随访60个月,范围25-92个月)。
- 两组在MFS、PFS和OS上均无显著差异(所有p>0.05)。
- 单因素和多因素分析中,T3-4和Gleason 4-5级预测BPFS。
- T分期、R状态(R1,2)和Gleason分级影响PFS;Gleason分级预测MFS;T分期预测OS。
- 多因素分析中,PSA持续不能预测任何生存结局(所有p>0.05)。
关键数值与推荐
- 欧洲前列腺癌指南对根治性切除术后持续PSA患者行SRT时加用ADT为「弱」推荐。
- 本研究SRT前PSA≤0.3 ng/ml,术后PSA≤0.05 ng/ml定义为从不可测水平升高,>0.05 ng/ml定义为持续PSA。
临床怎么用
- 对于根治性切除术后低持续PSA(>0.05 ng/ml)且无其他危险因素的患者,早期SRT时可能可省略ADT。
- PSA持续状态本身在多因素分析中不预测生存结局,决策时应结合T分期、Gleason分级和R状态等因素。
局限性
- 回顾性研究设计。
- 需要前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TITLE: Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis. INTRODUCTION: European prostate cancer guidelines include a "weak" recommendation to add hormonal therapy (ADT) to salvage radiotherapy (SRT) for better prognosis with persistent PSA values after radical prostatectomy (RP). In this study, prognosis with persistent PSA versus a PSA increase above undetectable after RP was compared. METHODS: In this retrospective study of patients who underwent SRT to the prostate bed without ADT (pre-SRT-PSA ≤ 0.3 ng/ml), 243 patients had a PSA increase from undetectable (post-op PSA ≤ 0.05 ng/ml), and 110 patients had persisting PSA after RP (post-op PSA > 0.05 ng/ml). Primary endpoints: clinical progression-free survival (PFS), biochemical PFS (BPFS), metastasis-free survival (MFS), overall survival (OS). Results: BPFS rates were 66.4% with low persistent PSA versus 71.6% with recurrent PSA (p = 0.253; median follow-up, 60 [25-92] months). The low-persistent and recurrent groups also did not differ for MFS, PFS, or OS (all p > 0.05). In univariate and multivariate analyses, T3-4 and Gleason grade 4-5 predicted BPFS; T-status, R-status (R1,2), and Gleason grade influenced PFS; Gleason grade predicted MFS; and T-status predicted OS. In multivariate analysis, PSA persistence did not predict any survival outcomes (all p > 0.05). CONCLUSION: Prognosis with low persistent PSA values seems comparable to that with PSA levels increasing above undetectable. In the absence of other factors, ADT could be omitted in this favorable patient group. Prospective trials are needed.
引用
- Thamm R, Scharl S, Gartner L, et al. Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis. Clin Transl Radiat Oncol. 2026. PMID: 41756146. doi:10.1016/j.ctro.2026.101121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。